Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23270834 | 0.92 | MDM2 (0.49) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL23270833 | 0.92 | MDM2 (0.49) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL28982176 | 0.91 | MDM2 (0.48) | MDM2MDM4TP53KMT2ACASP3 | |
| SCHEMBL30403561 | 0.91 | MDM2 (0.48) | MDM2MDM4TP53KMT2ACASP3 | |
| SCHEMBL30385583 | 0.91 | MDM2 (0.48) | MDM2MDM4TP53KMT2ACASP3 | |
| SCHEMBL28982175 | 0.91 | MDM2 (0.48) | MDM2MDM4TP53KMT2ACASP3 | |
| SCHEMBL23080684 | 0.89 | MDM2 (0.43) | MDM2MDM4TP53KMT2ACASP3 | |
| SCHEMBL1105517 | 0.89 | MDM2 (0.46) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL12361310 | 0.89 | MDM2 (0.46) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL13654219 | 0.89 | MDM2 (0.46) | MDM2MDM4TP53KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | MDM2 4586/4885MDM4 4847/4885TP53 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.